Zymeworks Inc.

Zymeworks Inc. is not a good value stock. Zymeworks Inc. is not a good growth stock. Zymeworks Inc. is not very popular among insiders. Zymeworks Inc. is a mediocre stock to choose.

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, devel...

News

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Globe Newswire VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...\n more…

Zymeworks Announces Participation in Upcoming Investor Conferences

Globe Newswire VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...\n more…

Buy Rating on Zymeworks Stock Amid Anticipated Zani Approval and Strategic Capital Allocation

TipRanks Financial Blog Zymeworks (ZYME - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Derek Archila from Wel...\n more…

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Simply Wall St Zymeworks Inc. ( NASDAQ:ZYME ) shareholders will have a reason to smile today, with the analysts making substantial...\n more…

Zymeworks Inc. 2024 Q2 - Results - Earnings Call Presentation

SeekingAlpha Zymeworks Inc. 2024 Q2 - Results - Earnings Call Presentation...\n more…

Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago. These figures are...\n more…